WOONSOCKET, R.I. (AP/WPRI) — CVS has halted sales of popular heartburn treatment Zantac and the store generic version after warnings by U.S. health regulators.
Woonsocket-based CVS is the latest retailer to pull the heartburn tablets from store shelves. Earlier this month, the U.S. Food and Drug Administration warned consumers about a potentially dangerous contaminant in prescription and over-the-counter versions of Zantac.
“This action is being taken out of an abundance of caution due to a recent Product Alert from the U.S. Food and Drug Administration (FDA) that ranitidine products may contain a low level of nitrosodimethylamine (NDMA), which is a probable human carcinogen,” CVS said in a statement.
The company said Zantac brand products and CVS brand ranitidine products have not been recalled, and the FDA is not recommending that patients stop taking ranitidine at this time.
In its announcement this weekend, CVS said customers who bought Zantac products can return them for a refund. The retailer will continue to sell other heartburn medications such as Pepcid.
Some manufacturers of the drug have stopped distribution. Health officials say concerned patients should consult their doctor.